Synthego, the genome engineering company, announced that it raised $100 million in a Series D financing led by new investor Wellington Management, co-led by RA Capital Management and 8VC. Other investors that participated included Founders Fund, Menlo Ventures, and Intel Capital. This new round brings Synthego’s total private funding to more than $250 million. Also,…
GentiBio, a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, announced that it has closed a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. GentiBio also announced it has entered into exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya…